# A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

> **NCT00356681** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 282 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Tumors
- Breast Cancer
- Locally Recurrent and Metastatic Breast Cancer

## Interventions

- **DRUG:** AMG 706 placebo
- **DRUG:** Bevacizumab
- **DRUG:** AMG 706
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00356681
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-02
- **Final completion:** 2012-08
- **Target enrollment:** 282 (ACTUAL)
- **Why stopped:** Sponsor decision to close study
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356681, "A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00356681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*